Panaji Journal

Several pharmaceutical companies are evaluating their drug candidates, resulting in a strong Respiratory Syncytial Virus pipeline

 Breaking News
  • No posts were found

Several pharmaceutical companies are evaluating their drug candidates, resulting in a strong Respiratory Syncytial Virus pipeline

June 11
20:25 2021
Several pharmaceutical companies are evaluating their drug candidates, resulting in a strong Respiratory Syncytial Virus pipeline

Respiratory Syncytial Virus Pipeline
DelveInsight’s Respiratory Syncytial Virus (RSV) Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects for the Respiratory Syncytial Virus (RSV) market. The disease summary and Respiratory Syncytial Virus treatment guidelines are included in this complete description of the Respiratory syncytial virus pipeline landscape.

DelveInsight’s Respiratory Syncytial Virus (RSV) Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects for the Respiratory Syncytial Virus (RSV) market. The disease summary and Respiratory Syncytial Virus treatment guidelines are included in this complete description of the Respiratory syncytial virus pipeline landscape.

Some Key Highlights from the Respiratory Syncytial Virus Pipeline Report

  • Pharmaceutical companies such as MedImmune LLC (AstraZeneca), Janssen Sciences Ireland UC, Meissa Vaccines, Inc., ReViral Ltd, Codagenix, Inc, ModernaTX, Inc., Virometix, Vaxart, Inc., and others are among the companies developing new drug candidates to improve the Respiratory Syncytial Virus pipeline landscape.

  • Respiratory Syncytial Virus pipeline therapies such as MEDI8897 and JNJ-53718678 are in the Phase III of clinical trials while therapies such as MV-012-968 and RV521 are in the Phase II of clinical trials.

  • CodaVax-RSV, mRNA-1345 and V-306 are among the pipeline therapies for Respiratory Syncytial Virus which are in the Phase I of clinical trials.

  • Respiratory Syncytial Virus pipeline therapy such as RSV-F is in the early stage of development i.e. early Phase I of clinical trials.

To know more, request sample @ Respiratory Syncytial Virus Pipeline Analysis

Respiratory Syncytial Virus: Overview

The Respiratory Syncytial Virus, or RSV, is a common respiratory virus that causes mild, cold-like symptoms in most people. Although most people recover in a week or two, RSV can be dangerous, particularly for infants and the older adults. In fact, in the United States, RSV is the most prevalent cause of bronchiolitis (inflammation of the tiny airways in the lungs) and pneumonia (lung infection) in children under the age of one year. It’s also a major cause of respiratory problems in the elderly.

Respiratory Syncytial Virus: Symptoms

Runny nose, loss of appetite, coughing, sneezing fever, and wheezing are common symptoms of RSV infection. These signs and symptoms typically occur in stages rather than all at once.

Respiratory Syncytial Virus Pipeline Analysis: Drug Profile

RSVpreF: Pfizer

Product Description

The RSVpreF vaccine candidate is based on the RSV fusion protein’s perfusion form. The vaccination stimulates the development of serum anti-F immunoglobulin G in pregnant women, which can then be passed to the foetus through the placenta and give protection for the first six months of life, when the risk of hospitalization is greatest.

Research and Development in the Respiratory Syncytial Virus Pipeline Landscape

Phase III

NCT04424316: Pfizer began a Phase 3 multicenter, randomised, double-blinded, placebo-controlled study in June 2020 to evaluate the efficacy, safety, and immunogenicity of RSVpreF or placebo (1:1 randomization) in infants born to healthy women who had been vaccinated during pregnancy, as well as the safety and immunogenicity in the pregnant women.

EDP-938: Enanta Pharmaceuticals

Product Description

Enanta has chosen EDP-938 as its first RSV development candidate because it is a powerful non-fusion inhibitor of both RSV-A and RSV-B activities

Research and Development in the Respiratory Syncytial Virus Pipeline Landscape

Phase II

NCT04633187: Enanta began a Phase 2b, randomised, double-blind, placebo-controlled, multicenter research in December 2020 to assess the efficacy and safety of EDP-938 in Adult Hematopoietic Cell Transplant patients with acute RSV infection and Upper Respiratory Tract symptoms.

Respiratory Syncytial Virus Pipeline Therapies and Key Companies

  • MEDI8897: MedImmune LLC (AstraZeneca)

  • JNJ-53718678: Janssen Sciences Ireland UC

  • MV-012-968: Meissa Vaccines, Inc.

  • RV521: ReViral Ltd

  • CodaVax-RSV: Codagenix, Inc

  • mRNA-1345: ModernaTX, Inc.

  • V-306: Virometix

  • RSV-F: Vaxart, Inc.

Reach out for more @Respiratory Syncytial Virus Treatment Landscape

Respiratory Syncytial Virus Therapeutics Assessment 

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

    • Protease

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Respiratory Syncytial Virus Key Players: MedImmune LLC (AstraZeneca), Janssen Sciences Ireland UC, Meissa Vaccines, Inc., ReViral Ltd, Codagenix, Inc, ModernaTX, Inc., Virometix, Vaxart, Inc., among others

Respiratory Syncytial Virus Pipeline Therapies: MEDI8897, JNJ-53718678, MV-012-968, RV521, CodaVax-RSV, mRNA-1345, V-306, RSV-F,  and others

Table of Contents

1.

Introduction

2.

Executive Summary

3.

Respiratory Syncytial Virus (RSV): Overview

4.

Respiratory Syncytial Virus (RSV)- Analytical Perspective In-depth Commercial Assessment

5.

Pipeline Therapeutics

6.

Late Stage Products (Phase III)

7.

Mid Stage Products (Phase II)

8.

Early Stage Products (Phase I)

9.

Therapeutic Assessment

10.

Inactive Products

11.

Company-University Collaborations (Licensing/Partnering) Analysis

12.

Respiratory Syncytial Virus (RSV) Key Companies

13.

Respiratory Syncytial Virus (RSV) Key Products

14.

Respiratory Syncytial Virus (RSV)- Unmet Needs

15.

Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers

16.

Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion

17.

Respiratory Syncytial Virus (RSV) Analyst Views

18.

Appendix

19.

About DelveInsight

Key questions answered in the Respiratory Syncytial Virus Pipeline Report

  • What are the different forms of therapy for Respiratory Syncytial Virus?

  • How many companies are working on drugs to treat Respiratory Syncytial Virus?

  • Which drugs from these companies are the most popular?

  • How many Respiratory Syncytial Virus medicines has each company produced in total?

  • How many novel therapies for Respiratory Syncytial Virus are currently being developed in the early, mid, and late stages?

  • How many of the drugs under development can be used alone or in combination with other treatments?

  • What are the most important industry-industry and industry-academy cooperation, mergers and acquisitions, and licensure practises affecting Respiratory Syncytial Virus?

Related Reports

Acute Respiratory Distress Syndrome Pipeline Insights

Get comprehensive analysis of Acute Respiratory Distress Syndrome pipeline therapies and key companies including Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Bayer, Altor BioScience, among others.

Related Posts 

For rich insights into rsv visit, RSV Pipeline Landscape

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles